Abstract 271P
Background
To assess the cost-effectiveness of pembrolizumab monotherapy (P) for CPS ≥1 subpopulation and in combination with platinum+5-FU chemotherapy (P+C) for the overall population versus cetuximab+platinum+5-FU chemotherapy (EXTREME regimen: E) for the first line treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in Taiwan.
Methods
A cohort-based partitioned survival model consisting of three health states (progression-free, progressed disease, and death) was developed. Using overall survival and progression free survival data from the P and P+C vs E arms of the KEYNOTE-048 study, the proportion of patients in each health state was estimated by parametric modeling over a 10-year period. Healthcare resource utilization data and costs per unit were sourced from the Taiwan National Healthcare Insurance Research Database, Cancer Registry database based on Taiwan National Health Insurance Administration (NHIA) reimbursement prices.
Results
In the base case analysis, P and P+C resulted in higher costs vs E (P: $1,964,859 vs E: $1,200,788 in the CPS ≥1 population; P+C: $2,301,474 vs E: $1,236,156 in the overall population), and higher quality adjusted life years (QALYs: P:1.22 vs 0.73 in the CPS ≥1 population; P+C: 1.30 vs 0.74 in the overall population). The incremental cost effectiveness ratio (ICER) for P vs E was NT$1,571,914/QALY in the CPS ≥1 population, and NT$1,912,195/QALY for P+C vs E in the overall population, respectively. At a willingness-to-pay threshold of 3 times Taiwan per capita Gross Domestic Product (GDP: NT$2,309,934), the resultant incremental cost/QALY for both P and P+C are considered cost-effective.
Conclusions
Both P and P+C are projected to be cost-effective options compared with E for the first-line treatment of R/M HNSCC patients. These results reflect the assumption of the publicly known pembrolizumab price in Taiwan; the price under managed entry agreement with NHIA may result in lower ICERs further demonstrating greater cost-effectiveness value.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
MSD LLC Taiwan Branch, Taiwan.
Funding
MSD LLC Taiwan Branch, Taiwan.
Disclosure
C.H. Wang: Advisory/Consultancy: Merck Sharp & Dohme (I.A.) LLC Taiwan Branch. All other authors have declared no conflicts of interest.
Resources from the same session
349P - Proteinuria in patients treated with ramcirumab increases the risk of renal dysfunction
Presenter: Kenta Hayashino
Session: e-Poster Display Session
350P - Rheumatologic immune related adverse events (irAEs) secondary to immune checkpoint inhibitor (ICI) therapy: A Western Australia experience
Presenter: Azim Khan
Session: e-Poster Display Session
351P - Valvular heart diseases in patients treated for breast cancer
Presenter: Ekaterina Kushnareva
Session: e-Poster Display Session
352P - Reproductive system disorders following chemotherapy in patients with breast cancer in Yogyakarta, Indonesia
Presenter: Irfan Haris
Session: e-Poster Display Session
353P - Survey for geriatric assessment in practising oncologists in India
Presenter: Vikas Talreja
Session: e-Poster Display Session
354P - Knowledge, perception, and attitude of oncology-related healthcare providers on complementary and alternative medicine (CAM)
Presenter: Chih Kiang Tan
Session: e-Poster Display Session
355P - Impact of comorbidities and rurality on treatment commencement, completion and outcomes, and health related quality of life, for geriatric oncology patients: Preliminary findings from a regional Australian study
Presenter: Mathew George
Session: e-Poster Display Session
357P - Comparison between immunotherapy and chemotherapy as neoadjuvant setting in resectable non-small cell lung cancer: A systematic review and meta-analysis of prospective trials
Presenter: Chao Zhang
Session: e-Poster Display Session
358P - Adjuvant tyrosine kinase inhibitors in non-squamous non-small cell lung cancer with EGFR driver mutations: An updated meta-analysis of randomized trials
Presenter: Joanmarie Balolong-Garcia
Session: e-Poster Display Session
359P - The role of adjuvant targeted therapy for postoperative EGFR mutant non-small cell lung cancer: A network meta-analysis
Presenter: Guang Ling Jie
Session: e-Poster Display Session